Claims for Patent: 9,643,995

Summary for Patent: 9,643,995

Title:	Triterpene glycoside and triterpene compositions and methods of using same
Abstract:	In the present invention, different strategies are used to improve the bioavailability of triterpene glycosides and triterpenes including, for example, (a) a covalent approach involving modification with polyethylene glycol and (b) a formulation approach involving non-covalent encapsulation in antibody targeted pol(DL-lactic acid) nanoparticles.
Inventor(s):	Einbond; Linda Saxe (Crestwood, NY), Raja; Krishnaswami (Staten Island, NY)
Assignee:	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY)
Application Number:	14/158,616
Patent Claims:	1. A method of treating cancer in a patient in need thereof with the administration of nanoparticles of ##STR00010## wherein MBS is a maleimidobenzoyl-N-hydroxy sulfosuccinimide ester activated antibody, wherein the sulfo-MBS activated antibody is anti-Her2; wherein the ##STR00011## is a poly(DL-lactic acid) nanoparticle loaded with triterpene glycoside or triterpene, wherein .quadrature. is a chemotherapeutic agent and is a triterpene glycoside and/or triterpene; wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, 5-FU, trastuzumab, tamoxifen, sulindac sulfide, thapsigargin and MEK inhibitor U0126; and wherein the cancer is selected from the group consisting of breast, prostate, oral, skin, colon and liver cancer. 2. The method of claim 1 wherein the triterpene glycoside is PEGylated. 3. The method according to claim 1 wherein the chemotherapeutic agent is paclitaxel. 4. The method according to claim 1 wherein the chemotherapeutic agent is trastuzumab. 5. The method according to claim 1 wherein the triterpene glycoside is actein. 6. A nanoparticle comprising: ##STR00012## wherein MBS is a maleimidobenzoyl-N-hydroxy sulfosuccinimide ester activated antibody, wherein the sulfo-MBS activated antibody is anti-Her2; wherein the ##STR00013## is a poly(DL-lactic acid) nanoparticle loaded with triterpene glycoside or triterpene, wherein .quadrature. is a chemotherapeutic agent and is a triterpene glycoside and/or triterpene; and wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, 5-FU, trastuzumab, tamoxifen, sulindac sulfide, thapsigargin and MEK inhibitor U0126. 7. The nanoparticle according to claim 6 wherein the triterpene glycoside is actein. 8. A method of treating cancer in a patient in need thereof with the administration of nanoparticles of ##STR00014## wherein MBS is a maleimidobenzoyl-N-hydroxy sulfosuccinimide ester activated antibody, wherein the sulfo-MBS activated antibody is anti-Her2; wherein ##STR00015## is a poly(DL-lactic acid) nanoparticle comprising paclitaxel (.quadrature.) and actein (.DELTA.); wherein the cancer is selected from the group consisting of breast, prostate, oral, skin, colon, and liver cancer.

Details for Patent 9,643,995

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-01-17
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-01-17
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2033-01-17